

References

- Abramowicz, Michael. 2003. Perfecting patent prizes. *Vanderbilt Law Review* 56, no. 1: 114–236.
- Adams, Christopher P., and Van V. Brantner. 2006. Estimating the cost of new drug development: Is it really \$802 million? *Health Affairs* 25, no. 2: 420–8.
- Allan, G. Michael, Joel Lexchin, Natasha Wiebe. 2007. Physician awareness of drug cost: A systematic review. *PLoS Medicine* 4, no. 9: 1486–96.
- Angell, Marcia. 2004. *The Truth about the Drug Companies*. New York: Random House.
- Alston, Philip and Katarina Tomaševski, eds. 1984. *The Right to Food*. Dordrecht: Martinus Nijhoff Publishers.
- Arrow, Kenneth. 1963. Uncertainty and the Welfare Economics of Medical Care. *American Economic Review* 53, no. 5: 941–73.
- Ashburn, Ted, and Karl Thor. 2004. Drug repositioning: identifying and developing new uses for Existing Drugs. *Nature Reviews Drug Discovery* 3, no. 8: 673–83.
- Avorn, Jerry. 2004. *Powerful Medicines*. New York: Alfred Knopf.
- Baker, Dean. 2004. Financing drug research: What are the issues? Issue Brief, Center for Economic and Policy Research, Washington, DC. http://www.cepr.net/documents/publications/intellectual_property_2004_09.pdf.
- Barber, Sarah and Paul Gertler. 2007. Empowering Women: How Mexico's Opportunities Improved Prenatal Care Quality and Birth Outcomes. Washington DC; World Bank.
- Bate R., P. Coticelli, R. Tren, A. Attaran. 2008. Antimalarial Drug Quality in the Most Severely Malarious Parts of Africa: A Six Country Study. *PLoS ONE* 3, no. 5: e2132.
- Berndt, Ernst R., Rachel Glennerster, Michael R. Kremer, Jean Lee, Ruth Levine, Georg Weizsacker, and Heidi Williams. 2007. Advance market commitments for vaccines against neglected diseases: Estimating costs and effectiveness. *Health Economics* 16, no. 5: 491–511.
- Birdsall, Nancy. 2007. Foreign aid: Diagnosis without direction. Review of *The White Man's Burden: Why the West's Efforts to Aid the Rest Have Done So Much Ill and So Little Good*, by William Easterly. Center for Global Development. <http://www.cgdev.org/content/opinion/detail/14519/>.
- Bessen, James and Michael Meurer. 2008. *Patent Failure*. Princeton: Princeton University Press.
- Board on Health Care Services. 2008. *Knowing What Works in Health Care: A Roadmap for the Nation*. Washington, DC: National Academies Press.
- CBO (US Congressional Budget Office). 2006. Research and Development in the Pharmaceutical Industry. CBO Report. Washington DC: CBO. <http://www.cbo.gov/ftpdocs/76xx/doc7615/10-02-DrugR-D.pdf>.

134 THE HEALTH IMPACT FUND

- CDC (Centers for Disease Control and Prevention). 2007. Leishmaniasis fact sheet. CDC Division of Parasitic Diseases: Parasitic Disease Information. http://www.cdc.gov/ncidod/dpd/parasites/leishmania/factsht_leishmania.htm.
- CDER (Center for Drug Evaluation and Research; US Food and Drug Administration) Handbook. <http://www.fda.gov/cder/handbook/>
- CGD (Center for Global Development). 2005. *Making Markets for Vaccines: Ideas for Action*. Washington, DC: Center for Global Development. <http://www.cgdev.org/doc/books/vaccine/MakingMarkets-complete.pdf>.
- . 2007. *Does the IMF Constrain Health Spending in Poor Countries? Evidence and an Agenda for Action*. Report of the Working Group on IMF Programs and Health Spending. http://www.cgdev.org/doc/IMF/IMF_Report.pdf.
- Chalker, J. 2005. Improving access or just pushing drugs? The importance of monitoring quality of care. Presentation abstract, SEAM (Strategies for Enhancing Access to Medicines) conference on targeting improved access to essential medicines, June 20–22, Accra. http://www.msh.org/seam/conference2005/pdf/Day1/14_Tr01_Chalker_abs.pdf.
- Chaudhuri, Sudip. 2007. Is product patent protection necessary in developing countries for innovation? R&D by Indian pharmaceutical companies after TRIPS. Indian Institute of Management Calcutta Working Paper Series no. 614.
- Chen, Shaohua and Martin Ravallion. 2007. Absolute poverty measures for the developing world, 1981–2004. *Proceedings of the National Academy of Sciences* 104, no. 43: 16757–62.
- Chirac, Pierre and Els Torreele. 2006. Global Framework on Essential Health R&D. *Lancet* 367(9522): 1560–1.
- Clemens, Michael A. and Gunilla Pettersson. 2008. New data on African health professionals abroad. *Human Resources for Health* 6, no. 1.
- CMS. 2007. National Health Expenditure Projections 2007–2017. Washington: Office of the Actuary in the Centers for Medicare & Medicaid Services.
- Cockburn, Iain M. and Rebecca Henderson. 2000. Publicly Funded Science and the Productivity of the Pharmaceutical Industry. *Innovation Policy and the Economy* 1: 1–34.
- Cohn Jay N., 2004. Introduction to surrogate markers. *Circulation* 109, no. 4: 20–1.
- Connor, Steve. 2008. Malaria: A miracle in the making offers hope to millions worldwide. *Independent* (London), June 4. <http://www.independent.co.uk/life-style/health-and-wellbeing/health-news/malaria-a-miracle-in-the-making-offers-hope-to-millions-worldwide-839604.html>.
- Correa, Carlos Maria. 2006. Implications of bilateral free trade agreements on access to medicines. *Bulletin of the World Health Organisation*. 84, no. 5: 399–404.
- Danzon, Patricia M. and Adrian Towse. 2003. Differential pricing for pharmaceuticals: Reconciling access, R&D and patents. *International Journal of Health Care Finance and Economics* 3, no. 3: 183–205.
- Das, Jishnu, Jeffrey Hammer and Kenneth Leonard. 2008. The Quality of Medical Advice in Low-Income Countries. *Journal of Economic Perspectives*, 22, no. 2: 93–114.
- Davies, James B., Susanna Sandstrom, Anthony Shorrocks, and Edward N. Wolff. 2006. *The World Distribution of Household Wealth*. Tokyo: UNU-WIDER.
- Deloitte. 2005. The Future of the life sciences. White paper in collaboration with the Economist Intelligence Unit. Deloitte Touche Tohmatsu. 2005. http://www.deloitte.com/dtt/cda/doc/content/DTT_Lifesciences_survey.pdf.
- DiMasi, Joseph A., Ronald W. Hansen and Henry G. Grabowski. 2003. The price of innovation: New estimates of drug development costs. *Journal of Health Economics* 22: 151–85.
- DiMasi, J. A., and H. G. Grabowski. 2007. The cost of biopharmaceutical R&D: Is biotech different? *Managerial and Decision Economics* 28, no. 4–5: 469–79.
- DiMasi, Joseph A., and C. Paquette. 2004. The economics of follow-on drug research and development: Trends in entry rates and the timing of development. *Pharmacoeconomics* 22, supp. 2: 1–14.

- DFID (UK Department for International Development). 2006. Factsheet: Access to medicines. UK Department for International Development Practice Paper. <http://www.dfid.gov.uk/pubs/files/atm-factsheet0106.pdf>.
- Drucker, Peter. 2006. *Classic Drucker: Essential Wisdom of Peter Drucker from the Pages of Harvard Business Review*. Cambridge: Harvard Business Publishing.
- Drummond, Michael F., Mark J. Sculpher, George W. Torrance, Bernie J. O'Brien, and Greg L. Stoddart. 2005. *Methods for the Economic Evaluation of Health Care Programmes*. 3rd ed. Oxford: Oxford University Press.
- Easterly, William. 2006. *The White Man's Burden: Why the West's Efforts to Aid the Rest Have Done So Much Ill and So Little Good*. Oxford: Oxford University Press.
- Eide, Asbjorn, Wenche Barth Eide, Susantha Goonatilake, and Joan Gussow, eds. 1984. *Food as a Human Right*. Tokyo: United Nations University Press.
- Evans, David B, Tessa Tan-Torres Edejer, Taghreed Adam, Stephen S Lim. 2005. Methods to assess the costs and health effects of interventions for improving health in developing countries. *BMJ* 331: 1137–40.
- Eyal, Nir and Samia A Hurst. 2008. Physician brain drain: Can nothing be done? *Public Health Ethics* 1, Advanced Access online. <http://phe.oxfordjournals.org/cgi/content/full/phn026>.
- Farlow, Andrew W. K., Donald W. Light, Richard T. Mahoney, and Roy Widdus. 2005. Concerns regarding the Center for Global Development report "Making markets for vaccines." Submission to WHO Commission on Intellectual Property Rights, Innovation and Public Health. <http://www.who.int/intellectualproperty/submissions/Vaccines.FarlowLight.pdf>.
- Faunce, Thomas Alured and Hitoshi Nasu. 2008. Three proposals for rewarding novel health technologies benefiting people living in poverty: A comparative analysis of prize funds, health impact funds and a cost-effectiveness/competitive tender treaty. *Public Health Ethics* 1, Advanced Access online. <http://phe.oxfordjournals.org/cgi/reprint/phn013v1>.
- Flynn, Sean, Aidan Hollis, and Mike Palmedo. 2008. An Economic Justification for Open Access to Essential Medicine Patents in Developing Countries. *Mimeo*.
- Fogarty (John Fogarty International Center for Advanced Study in the Health Sciences). n.d. Executive Summary: Strategic Plan Fiscal Years 2000–2003. http://www.fic.nih.gov/about/plan/exec_summary.htm (accessed June 9, 2008).
- Food and Drug Administration Amendments Act of 2007. Signed into law September 27, 2007 as Public Law 110-85.
- GAO (US Government Accountability Office). 2006. New Drug Development: Science, Business, Regulatory, and Intellectual Property Issues Cited as Hampering Drug Development Efforts. GAO-07-49. <http://www.gao.gov/new.items/d0749.pdf>
- Garnier, J.-P. 2008. Rebuilding the R&D engine in Big Pharma. *Harvard Business Review*, May: 68–77.
- GHWA (Global Health Workforce Alliance). 2008a. Health workers for all and all for health workers: An agenda for global action. GHWA. http://www.who.int/workforcealliance/forum/1_agenda4GAction_final.pdf.
- . 2008b. Scaling up, saving lives. Report of the Task Force for Scaling Up Education and Training for Health Workers. GHWA. http://www.who.int/workforcealliance/documents/Global_Health%20FINAL%20REPORT.pdf.
- Global Forum on Health Research. 2004. *The 10/90 Report on Health Research 2003–2004*. Geneva: GFHR.
- Global Fund (The Global Fund to Fight AIDS, Tuberculosis and Malaria). 2007. By-laws. Global Fund. http://www.theglobalfund.org/en/files/about/governance/Bylaws_governance.pdf.

136 THE HEALTH IMPACT FUND

- Go A. S., J. Yang, J. H. Gurwitz, J. T. Hsu, K. Lane, R. Platt. Comparative effectiveness of beta-adrenergic antagonists on the risk of rehospitalization in adults with heart failure. 2007 *Effective Health Care Research*, no. 3. Prepared by HMO Research Network DEcIDE Center Under Contract No. HSA29020050033I. Rockville, MD: Agency for Healthcare Research and Quality. <http://www.effectivehealthcare.ahrq.gov/reports/final.cfm>.
- Gwatkin, David R. and Michel Guillot. 2000. *The Burden of Disease among the Global Poor: Current Situation, Future Trends, and Implications for Strategy*. Washington, DC, and Geneva: World Bank and Global Forum for Health Research. [http://wbln0018.worldbank.org/hdnet/hddocs.nsf/c840b59b6982d2498525670c004def60/12783cdd120daff285256aa800681d44/\\$FILE/Gwatkin%20-%20The%20burden%20of%20disease.pdf](http://wbln0018.worldbank.org/hdnet/hddocs.nsf/c840b59b6982d2498525670c004def60/12783cdd120daff285256aa800681d44/$FILE/Gwatkin%20-%20The%20burden%20of%20disease.pdf).
- HAI (Health Action International). 2004. Medicine prices in Ghana: A comparative study of public, private and mission sector medicine prices. HAI. <http://www.haiweb.org/medicineprices/surveys/200410GH/sdocs/Ghana.pdf>.
- .2005. Survey of prices of medicines in Ethiopia 2005. HAI. <http://www.haiweb.org/medicineprices/surveys/200409ET/sdocs/surveyReport.pdf>.
- Hollis, Aidan. 2005a. An efficient reward system for pharmaceutical innovation. Manuscript. www.econ.ucalgary.ca/fac-files/ah/drugprizes.pdf.
- .2005b. Optional rewards for new drugs for developing countries. Manuscript. www.who.int/entity/intellectualproperty/submissions/Submissions.AidanHollis.pdf.
- .2006. Neglected disease research: Health needs and new models for R&D. In *The Power of Pills*, ed. J. Cohen, P. Illingworth, and U. Schuklenk, 125–133. London: Pluto Press.
- .2007a. A Comprehensive Advance Market Commitment. Submission to the World Health Organization Public Health, Innovation and Intellectual Property Intergovernmental Working Group, available at http://www.who.int/phi/public_hearings/second/contributions_section2/Section2_Aidan_Hollis_Full_Contribution.pdf.
- .2007b. Drugs for neglected diseases: New incentives for innovation. In *Pharmaceutical innovation: Incentives, competition, and cost-benefit analysis in international perspective*, ed. F. Sloan and C. Hsieh, 75–90. Cambridge: Cambridge University Press.
- .2007c. Incentive mechanisms for innovation. Manuscript. www.iapr.ca/iapr/files/iapr/iapr-tp-07005_0.pdf.
- Holve, E., and P. Pittman. 2008. Cost and Volume of Current Comparative Effectiveness Research. Presentation at Institute of Medicine Conference on Learning What Works, July 30–31, 2008. <http://www.iom.edu/CMS/28312/RT-EBM/55282/57193.aspx>.
- Hughes D., B. Tunnage, and S.T. Yeo. 2005. Drugs for exceptionally rare diseases: do they deserve special status for funding? *QJM* 98, no. 11: 829–36.
- ICIUM (International Conference on Improving Use of Medicines). 2004. Theme summaries. Second international conference on improving use of medicines: From vision to action, March 30–April 2, Chiang Mai, Thailand. <http://mednet3.who.int/icium/icium2004/recommendations.asp>.
- IEA (International Energy Agency). 2002. World energy outlook 2002 sees abundant energy until 2030, but projects challenges on security, investment, environment and poverty. Press release, September 21. http://www.iea.org/Textbase/press/pressdetail.asp?PRESS_REL_ID=70.
- ILO (International Labour Office). 2006. *The End of Child Labour: Within Reach*. Geneva: ILO. www.ilo.org/public/english/standards/relm/ilc/ilc95/pdf/rep-i-b.pdf.
- IMF (International Monetary Fund). 2007. IMF comments on “Does the IMF constrain health spending in poor countries.” IMF. <http://www.imf.org/external/np/vc/2007/062907.htm>.
- Institute of Medicine. 2004. *Saving Lives, Buying Time: Economics of Malaria in an Age of Resistance*. Washington, DC: National Academies Press.

- .2008. Learning What Works: Infrastructure Required to Learn Which Care is Best. Public Meeting July 30–31, 2008. <http://www.iom.edu/CMS/28312/RT-EBM/55282.aspx>.
- Jamison, Dean T., Joel G. Breman, Anthony R. Measham, George Alleyne, Mariam Claeson, David B. Evans, Prabhat Jha, Anne Mills, and Philip Musgrove, eds. 2006. *Priorities in Health*. Washington, DC: World Bank.
- Johnston, Josephine and Angela A. Wasunna. 2007. Patents, biomedical research, and treatments: Examining concerns, canvassing solutions. *Hastings Center Report* 37, no. 1: S1–36.
- Kennickell, Arthur. 2003. A rolling tide: Changes in the distribution of wealth in the US, 1989–2001 (FEDS Working Paper no. 2003–24). www.federalreserve.gov/Pubs/OSS/oss2/papers/concentration.2001.10.pdf.
- Kieff, F. Scott, 2001. Property rights and property rules for commercializing inventions. *Minnesota Law Review* 85: 697–754.
- Kremer, Michael. 1998. Patent Buyouts: A Mechanism for Encouraging Innovation. *Quarterly Journal of Economics* 113: 1137–67.
- Kremer, Michael and Rachel Glennerster. 2004. *Strong Medicine: Creating Incentives for Pharmaceutical Research on Neglected Diseases*. Princeton: Princeton University Press.
- Krupnick, A. 2004. Valuing Health Outcomes: Policy Choices and Technical Issues. Resources for the Future, Washington.
- Lewis, Maureen. 2007. Informal Payments And The Financing Of Health Care In Developing And Transition Countries. *Health Affairs* 26, no. 4: 984–97.
- Light, Donald W., and Rebecca N. Warburton. 2005. Extraordinary claims require extraordinary evidence. *Journal of Health Economics* 24: 1030–3.
- Love, James. 2005. Medical Research and Development Treaty. www.cptech.org/workingdrafts/rndtreaty4.pdf.
- Love, James and Tom Hubbard. 2007. The big idea: Prizes to stimulate R&D for new medicines. *Chicago-Kent Law Review* 82, no. 3: 1520–54.
- MacLean, C., A. Alexander, J. Carter, S. Chen, S. B. Desai, J. Grossman, M. Maglione, M. McMahon, M. McNamara, W. Mojica, S. Newberry, V. Ranganath, M. Suttorp, M. Timmer, C. Tringale, D. Valentine, and A. Zhou. 2007. Comparative effectiveness of treatments to prevent fractures in men and women with low bone density or osteoporosis. *Comparative Effectiveness Review*, no. 12. Prepared by Southern California/RAND Evidence-based Practice Center under Contract No. 290-02-0003. Rockville, MD: Agency for Healthcare Research and Quality. <http://www.effectivehealthcare.ahrq.gov/reports/final.cfm>.
- Mbwasi, R., M. Sigonda-Ndomondo, E. Alphonse, M. Clark, N. Heltzer and R. Shirima. 2005. Enhancing drug access through private and multi-sector initiatives: the Tanzania experience. Presentation abstract, SEAM (Strategies for Enhancing Access to Medicines) conference on targeting improved access to essential medicines, June 20–22, Accra. http://www.msh.org/seam/conference2005/pdf/Day1/08_Tr01_Mbwasi_abs.pdf (accessed January 10, 2008).
- McCaughan, Matthew. 2008. “Case-by-Case:” How One Company Assesses the Priority Voucher Program. *The RPM Report*. 3, no. 13 (July).
- McKinley, Terry. 2005. Why is “The Dutch Disease” always a Disease? The Macroeconomic Consequences of Scaling up ODA (UNDP International Poverty Centre Working Paper no. 10), <http://www.undp.org/povertycentre/newsletters/WorkingPaper10.pdf> (accessed June 16, 2008).
- Mensah, D. E. 2005. The chemical sellers’ franchise model: CAREshops in Ghana. Presentation abstract, Mensah, D E. 2005. The Chemical Sellers’ Franchise Model: CAREshops in Ghana. Presentation abstract, SEAM (Strategies for Enhancing Access to Medicines) conference on targeting improved access to essential medicines, June 20–22, Accra. http://www.msh.org/seam/conference2005/pdf/Day1/10_Tr01_Mensah_abs.pdf (accessed January 10, 2008).
- Mercurio, Bryan. 2006. Resolving the public health crisis in the developing world: Problems and barriers of access to essential medicines. *Northwestern Journal of International Human Rights* 5, no. 1: 1–40.

138 THE HEALTH IMPACT FUND

- Møldrup, Claus. 2005. No cure, no pay. *BMJ* 330: 1262–64.
- Morgan, Steven G. 2006. Prescription drug expenditures and population demographics. *Health Services Research* 41, no. 2: 411–28.
- MSF (Médecins Sans Frontières). 2007. *Untangling the Web of Price Reductions: A Pricing Guide for the Purchase of ARVs for Developing Countries*. 10th ed. http://www.accessmed-msf.org/fileadmin/user_upload/diseases/hiv-aids/Untangling_the_Web/UTW10_RSep_horizontal.pdf.
- Murray, Christopher J. L. 1994. Quantifying the Burden of Disease: the Technical Basis for Disability-Adjusted Life Years. *Bulletin of the World Health Organisation* 72, no. 3: 429–45
- Murray, Christopher J.L., and Arnab K. Acharya. 1997. Understanding DALYs. *Journal of Health Economics* 16: 703–30.
- Murray, Christopher J. L. and Alan D. Lopez. 1996. Evidence-based health policy: Lessons from the Global Burden of Disease Study. *Science* 274: 740–3.
- .1996. *The Global Burden of Disease: A Comprehensive Assessment of Mortality and Disability from Diseases, Injuries and Risk Factors in 1990 and Projected to 2020*. Cambridge, MA: Harvard School of Public Health.
- Murray, Christopher J. L., Joshua A. Salomon, Colin D. Mathers, Alan D. Lopez, eds. 2002. *Summary Measures of Population Health: Concepts, Ethics, Measurement and Applications*. Geneva: WHO.
- Nathan, Carl. 2007. Aligning pharmaceutical innovation with medical need. *Nature Medicine* 13, no. 3: 304–8.
- NICE (National Institute for Clinical Excellence) 2004.. New inquiry: The influence of the pharmaceutical industry. Submission to the Health Select Committee. NICE.
- NIH (National Institutes of Health). 2007. Summary of the FY 2008 President's budget. Bethesda, MD: National Institutes of Health. February 5. <http://www.nih.gov/about/director/budgetrequest/pressinfofy2008.pdf>.
- Nozick, Robert. 1974. *Anarchy, State, and Utopia*. New York: Basic Books.
- Organisation for Economic Co-operation and Development. n.d. Health at a Glance 2007: OECD Indicators. Chart g5-4-01 <http://miranda.sourceoecd.org/vl=2202827/cl=18/nw=1/rpsv/health2007/g5-4-01.htm>.
- Organisation for Economic Co-operation and Development and IRDES. 2007. *OECD Health Data 2007*. Paris: OECD.
- Ombogo, J. 2005. The child and family wellness shops micro-franchise system: A private sector model for improving access to essential medicines. Presentation abstract, SEAM (Strategies for Enhancing Access to Medicines) conference on targeting improved access to essential medicines, June 20–22, Accra. http://www.msh.org/seam/conference2005/pdf/Day1/12_Tr01_Ombogo_abs.pdf (accessed January 10, 2008).
- Ooms, Gorik and Rachel Hammonds. 2008. Correcting globalisation in health: Transnational entitlements versus the ethical imperative of reducing aid-dependency. *Public Health Ethics* 1, Advanced Access online. <http://phe.oxfordjournals.org/cgi/reprint/phn018>.
- Oster, G., G. M. Borok, J. Menzin, J. F. Heyse, R. S. Epstein, V. Quinn, V. Benson, R. J. Dudl, and A. M. Epstein. 1995. A randomized trial to assess effectiveness and cost in clinical practice: rational and design of the CRIS. *Controlled Clinical Trials* 16: 3–16.
- Outterson, K. and R. Smith. 2006. Counterfeit drugs: The good, the bad, and the ugly. *Albany Law Journal of Science and Technology* 16, no. 3: 525–544.
- PATH. n.d. Malaria Vaccine Initiative. <http://www.maliavaccine.org/> (accessed June 11, 2008).
- Pharmaceutical R&D Policy Project. 2005. *The Landscape of Neglected Disease Drug Development*. London: Wellcome Trust and London School of Economics.
- Pogge, Thomas. 2005. Human rights and global health: a research program. *Metaphilosophy* 36, no. 1/2: 1852–209.
- Pogge, Thomas. 2008a. Access to Medicines. *Public Health Ethics Public Health Ethics* 1, Advanced Access online. <http://phe.oxfordjournals.org/cgi/content/full/phn023>.

- Pogge, Thomas. 2008b. *World Poverty and Human Rights: Cosmopolitan Responsibilities and Reforms*. 2nd ed. Cambridge: Polity Press.
- . 2008c. Medicines for the world: Boosting innovation without obstructing free access. Portuguese trans. Pedro Maia Soares. Medicamentos para o mundo: fomentar a inovação sem obstruir o livre acesso. Spanish trans. Alex Ferrara. Medicamentos para el mundo: impulsar la innovación sin obstaculizar el libre acceso. *Sur: Revista Internacional de Derechos Humanos* 8.
- Revicki, Dennis A. and Lori Frank. 1999. Pharmaco-economic evaluation in the real world effectiveness versus efficacy studies. *Pharmacoeconomics* 15, no. 5: 423–34.
- Ridley, David B., Henry G. Grabowski, and Jeffrey L. Moe. 2006. Developing drugs for developing countries. *Health Affairs* 25, no. 2: 313–24.
- Rimmer, Matthew. 2008. Race against time: The export of essential medicines to Rwanda. *Public Health Ethics*, 1, Advanced Access online. <http://phe.oxfordjournals.org/cgi/reprint/phn011v1>.
- Roin, Benjamin. 2008. Unpatentable Drugs and the Standards of Patentability, *Texas Law Review* 87, forthcoming.
- Roland, Martin and David J. Torgerson. 1998. Understanding controlled trials: What are pragmatic trials? *British Medical Journal* 316: 285.
- Saez, Emmanuel and Thomas Piketty. 2003. Income inequality in the United States, 1913–1998. *Quarterly Journal of Economics* 118: 1–39.
- Schwartz, E. and J. Hsu. 2007. A model of R&D valuation and the design of research incentives (with a case study on vaccine development). Manuscript. <http://ssrn.com/abstract=1079609>.
- Scotchmer, S. 2004. *Innovation and Incentives*. Cambridge, MA: MIT Press.
- Scott, Kieff, F. 2001. Property rights and property rules for commercializing inventions. *Minnesota Law Review* 85: 697–754.
- Seidenfeld, J., M. Piper, J. Bohlius, O. Weingart, S. Trelle, A. Engert, N. Skoetz, G. Schwarzer, J. Wilson, S. Brunskill, C. Hyde, C. Bonnell, K. M. Ziegler, and N. Aronson. 2006. Comparative effectiveness of epoetin and darbepoetin for managing anemia in patients undergoing cancer treatment. *Comparative Effectiveness Review*, no. 3. Prepared by Blue Cross and Blue Shield Association Technology Evaluation Center Evidence-based Practice Center under Contract No. 290-02-0026. Rockville, MD: Agency for Healthcare Research and Quality. <http://www.effectivehealthcare.ahrq.gov/reports/final.cfm>.
- Selgelid, Michael J. 2007a. Ethics and drug resistance. *Bioethics* 21: 218–29.
- . 2007b. The importance of “throwing money at” the problem of global health. *Indian Journal of Medical Ethics* 4, no. 2: 73–5.
- . 2008a. Ethics, Tuberculosis and Globalization *Public Health Ethics* 1, no. 1: 10–20.
- . 2008b. A full pull program for the provision of pharmaceuticals: Practical issues. *Public Health Ethics* 1, Advanced Access online. <http://phe.oxfordjournals.org/cgi/content/full/phn022>.
- Shue, Henry. 1980. *Basic Rights*. Princeton: Princeton University Press.
- Stiglitz, Joseph E. 2006. Scrooge and intellectual property rights. *BMJ*, 333: 1279–1280.
- Stolberg, S. 2008. In global battle on AIDS, Bush creates legacy. *New York Times*, January 5. http://www.nytimes.com/2008/01/05/washington/05aids.html?_r=1&scp=1&sq=global+battle+aids+bush+legacy&oref=slogin.
- Summers, Lawrence. 1989. Some Simple Economics of Mandated Benefits. *American Economic Review* 79, no. 2: 177–83.
- Thuo, M. and J. Wachira. 2005. Development and implementation of standard operating procedures to improve the quality of pharmaceutical services in support of antiretroviral therapy: Experiences in Kenya. Presentation abstract, SEAM (Strategies for Enhancing Access to Medicines) conference on targeting improved access to essential medicines, June 20–22, Accra. http://www.msh.org/seam/conference2005/pdf/Day1/25_Tr02_Thuo_abs.pdf (accessed January 25, 2008).

140 THE HEALTH IMPACT FUND

- Trouiller, Patrice, Piero Olliaro, Els Torrelee, James Orbinski, Richard Laing, and Nathan Ford. 2002. Drug development for neglected diseases: A deficient market and a public-health policy failure. *Lancet* 359, no. 9324: 2188–94.
- Ubel, Peter A., Richard A. Hirth, Michael E. Chernew, A. Mark Fendrick. 2002. What is the price of life and why doesn't it increase at the rate of inflation? *Archives of Internal Medicine* 163: 1637–41.
- UN (United Nations). 2007. UN independent expert launches draft human rights guidelines for pharmaceutical companies. Press release, 19 September. <http://www.unhcr.ch/hurricane/hurricane.nsf/view01/497E81A16B31B9C8C125735B-0059D7B0?opendocument>.
- UN Millennium Project. 2005. *Prescription for Healthy Development: Increasing Access to Medicines*. Report of the Task Force on HIV/AIDS, Malaria, TB and Access to Essential Medicines, Working Group on Access to Essential Medicines. Sterling, VA: Earthscan. http://mirror.undp.org/unmillenniumproject/reports/tf_essentialmedecines.htm.
- UNAIDS (Joint United Nations Programme on HIV/AIDS). 2006. *Report on the Global Aids Epidemic*. Geneva: UNAIDS. http://data.unaids.org/pub/GlobalReport/2006/2006_GR_CH07_en.pdf.
- .2007a. Financial Resources Required to Achieve Universal Access to HIV Prevention, Treatment, Care and Support. Geneva: UNAIDS. http://data.unaids.org/pub/Report/2007/20070925_advocacy_grne2_en.pdf.
- .2007b. *AIDS Epidemic Update 2007*. Geneva: UNAIDS. http://data.unaids.org/pub/EPISlides/2007/2007_epiupdate_en.pdf.
- UNDP (United Nations Development Programme). 1998. *Human Development Report 1998*. New York: Oxford University Press. <http://hdr.undp.org/reports/global/1998/en/>.
- .2006. *Human Development Report 2006*. Basingstoke: Palgrave Macmillan. <http://hdr.undp.org/hdr2006/>.
- UNESCO (United Nations Educational, Scientific and Cultural Organization) Institute for Statistics. 2006. Literacy rates, youth (15–24) and adult (15+), by region and gender for 2000–2004 (April 2006 Assessment, updated 2006-09-08). http://www.uis.unesco.org/ev.php?ID=6562_201&ID2=DO_TOPIC.
- US Food and Drug Administration. 2005. CDER NDAs approved in calendar years 1990–2004 by therapeutic potential and chemical types. <http://www.fda.gov/cder/rdmt/pstable.htm>.
- Vogel, Ronald J. 2007. *Pharmaceutical Economics and Public Policy*. Binghamton, NY: Haworth Press.
- World Bank. 2007. *World Development Report 2007*. Washington, DC: World Bank. www.worldbank.org/wdr2007.
- WHO (World Health Organization). 2000. *Weekly Epidemiological Record*, no. 2. <http://www.who.int/docstore/wer/pdf/2000/wer7502.pdf>.
- .2001. African trypanosomiasis or sleeping sickness. WHO Fact Sheet, no. 259. <http://www.who.int/mediacentre/factsheets/fs259/en/>.
- .2004a. *Changing History: The World Health Report 2004*. Geneva: WHO. www.who.int/whr/2004.
- .2004b. *The World Medicines Situation*. Geneva: WHO. http://www.searo.who.int/LinkFiles/Reports_World_Medicines_Situation.pdf.
- .2005. *World Malaria Report*. Geneva, WHO. <http://www.rollbackmalaria.org/wmr2005/>.
- .2006a. Evaluation of WHO's Contribution to '3 by 5'. <http://www.who.int/hiv/topics/me/3by5%20Evaluation.pdf>.
- .2006b. Public Health, Innovation and Intellectual Property Rights: Report of the Commission on Intellectual Property Rights, Innovation and Public Health. Geneva: WHO. <http://www.who.int/intellectualproperty/documents/thereport/ENPublicHealthReport.pdf>.
- .2006c. *Rational Use of Medicines: Progress in Implementing the WHO Medicines Strategy*. Secretariat Report to the WHO Executive Board. May 11. http://www.who.int/gb/ebwha/pdf_files/EB118/B118_6-en.pdf.

- .2006d. *Working Together for Health: World Health Report 2006*. Geneva: WHO. <http://www.who.int/whr/2006/en/index.html>.
- .2006e. Counterfeit medicines. Fact Sheet 275. <http://www.who.int/mediacentre/factsheets/fs275/en/print.html>
- .2007. Intergovernmental Working Group on Public Health, Innovation and Intellectual Property. Draft global strategy and plan of action on public health, innovation and intellectual property. http://www.who.int/gb/phi/pdf/igwg2/PHI_IGWG2_CP1Rev1-en.pdf.
- .2008a. Nearly three million HIV-positive people now receiving life-saving drugs. But access to prevention and treatment still lacking for millions. Joint WHO/UNAIDS/UNICEF press release, June 2. <http://www.who.int/hiv/mediacentre/pressrelease2june2008/en/index.html>.
- .2008b. *Anti-Tuberculosis Drug Resistance in the World*. Report no. 4. Geneva: WHO. http://www.who.int/tb/publications/2008/drs_report4_26feb08.pdf.
- WIPO. 2007. WIPO Patent Report: Statistics on Worldwide Patent Activities (2007 Edition). Geneva: WIPO. http://www.wipo.int/ipstats/en/statistics/patents/patent_report_2007.html.
- Woods, Ngaire. 2000. The challenge of good governance for the IMF and the World Bank themselves. *World Development* 28, no. 5: 823-841.
- WTO (World Trade Organization). 2001. Declaration on the TRIPS Agreement and Public Health, Ministerial Conference. http://www.wto.org/English/thewto_e/minist_e/min01_e/mindecl_trips_e.htm.
- .2003. Implementation of Paragraph 6 of the Doha Declaration on the TRIPS Agreement and Public Health. http://www.wto.org/english/tratop_e/trips_e/implem_para6_e.htm.